Clover Health to Participate in Upcoming 2024 KeyBanc Technology Leadership Forum and Canaccord Genuity 44th Annual Growth Conference

Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced its participation in the following investor conferences:

• CFO, Peter Kuipers, will participate in a fireside chat presentation at the 2024 KeyBanc Technology Leadership Forum on Tuesday, August 6, 2024, at 3:00 p.m. Eastern Time.
• CEO, Andrew Toy, and CFO, Peter Kuipers, will participate in a fireside chat presentation at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024, at 2:00 p.m. Eastern Time.

A live webcast and reply of the fireside chat presentations will be accessible from Clover Health's investor relations website at https://investors.cloverhealth.com/.

About Clover Health:Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we aim to extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Press Contact:Andrew [e-mail]

Investor Relations Contact:Ryan [e-mail]